Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

Share Price is delayed by 15 minutes
Get Live Data
1.50    0.085 (4.96%)
Bid:
1.30
Ask:
2.30
Spread: 1.00 (76.923%)
Market Cap: £5.26m
PRM Live PriceLast checked at - London Stock Exchange

Intraday Proteome Share Chart

Directorate Change

1 Jul 2014 07:00

RNS Number : 9952K
Proteome Sciences PLC
01 July 2014
 



 

 

 

 

 

PRESS RELEASE

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Appointment of Roger McDowell as Non-Executive Director

 

1st July, 2014 Proteome Sciences is pleased to announce the appointment of Roger Steven McDowell to the Board of the Company as a non-executive Director with immediate effect.

 

Roger McDowell has a highly successful career as a businessman and entrepreneur. He was Managing Director of Oliver Ashworth for eighteen years before its sale to St. Gobain. He is currently the Chairman or a non-executive director of seven listed companies, namely Avingtrans plc, Servelec Group plc, Renovo plc, Alkane Energy plc, Swallowfield plc, IS Solutions plc and Augean plc. He brings considerable commercial experience with him and is a keen exponent of growing shareholder value.

 

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Roger Steven McDowell, age 60 years, is or has been a director of the following companies during the five years preceding the date of this announcement:

 

Current directorships Past directorships

Corsair Techinvest Ltd One Advice Group plc

Fineguard Ltd Ultimate Finance Group plc

Augean plc

Disperse Ltd

Dovehoco 201 Ltd

Avingtrans plc

IS Solutions plc

Swallowfield plc

Alkane Energy plc

Renovo plc

Servelec Group plc

 

There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies. 

 

At the AGM, held on 30 June 2014, it was announced that Steve Harris, the Chairman, was proposing to retire and he has now formally stepped down as a director.

 

The Board of Proteome Sciences would like to thank him for the considerable contribution and support that he has provided to the Company over the last 20 years, a period in which the Company's outstanding biomarker research has been converted into products, services and commercial revenue. We wish him a long and enjoyable retirement.

 

The CEO, Christopher Pearce, has been appointed Executive Chairman. Dr. Ian Pike remains the Chief Operating Officer.

 

 

- Ends -

 

 

 

 

 

 

For further information please contact:

Proteome Sciences plc

Christopher Pearce, Chief Executive Officer

Tel: +44 (0)1932 865065

Dr. Ian Pike, Chief Operating Officer

James Malthouse, Finance Director

Nominated Adviser

Cenkos

Stephen Keys/Callum Davidson

Tel: +44 (0)20 7397 8900

Public Relations

IKON Associates

Adrian Shaw

Tel: +44 (0)1483 271291

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAKBLFXZQFEBBD
Date   Source Headline
30th Jun 20104:27 pmRNSResult of AGM,Loan Conversion,Total Voting Rights
28th Jun 20105:59 pmRNSCOMPLETION OF PLACING AND OVERSUBSCRIBED OPEN OFFE
18th Jun 20107:00 amRNSUpdate on warranty claim
17th Jun 20109:00 amRNSReport and Accounts
11th Jun 20107:00 amRNSPublication of Circular
8th Jun 201011:21 amRNSHolding(s) in Company
7th Jun 20104:40 pmRNSSecond Price Monitoring Extn
7th Jun 20104:35 pmRNSPrice Monitoring Extension
7th Jun 20104:22 pmRNSPreliminary Results
7th Jun 20104:17 pmRNSPlacing, Open Offer & Loan Conversion
2nd Jun 20107:00 amRNSReimbursement of lung cancer test in USA
26th Apr 201011:55 amRNSBlocklisting Interim Review
9th Apr 20107:00 amRNSLicense Agreement
11th Feb 20108:18 amRNSAlliance with Parexel
9th Feb 20107:00 amRNSChange of Adviser
1st Feb 20102:01 pmRNSHolding(s) in Company
23rd Dec 20093:55 pmRNSDirectorate Change
16th Nov 20091:39 pmRNSHolding(s) in Company
28th Oct 20097:00 amRNSRe Contract
26th Oct 20097:00 amRNSBlock Admission
23rd Oct 20094:40 pmRNSSecond Price Monitoring Extn
23rd Oct 20094:35 pmRNSPrice Monitoring Extension
30th Sep 20097:00 amRNSHalf Yearly Report
25th Sep 20094:40 pmRNSSecond Price Monitoring Extn
25th Sep 20094:35 pmRNSPrice Monitoring Extension
10th Sep 20094:40 pmRNSSecond Price Monitoring Extn
10th Sep 20094:35 pmRNSPrice Monitoring Extension
9th Sep 20094:40 pmRNSSecond Price Monitoring Extn
9th Sep 20094:35 pmRNSPrice Monitoring Extension
28th Aug 20094:40 pmRNSSecond Price Monitoring Extn
28th Aug 20094:35 pmRNSPrice Monitoring Extension
16th Jul 20093:39 pmRNSHolding(s) in Company
14th Jul 200910:26 amRNSResult of AGM
6th Jul 20097:00 amRNSLicensing Agreement
30th Jun 20094:40 pmRNSSecond Price Monitoring Extn
30th Jun 20094:35 pmRNSPrice Monitoring Extension
22nd Jun 20098:00 amRNSPosting of Report & Accounts
18th Jun 20097:00 amRNSPreliminary Results
27th May 20097:00 amRNSLicense Agreement in Brain Damage
5th May 20092:40 pmRNSHolding(s) in Company
28th Apr 20092:20 pmRNSBlocklisting Interim Review
30th Mar 20097:00 amRNSChange of Adviser
23rd Mar 200910:30 amRNSHolding(s) in Company
18th Mar 20094:55 pmRNSHolding(s) in Company
9th Mar 20097:00 amPRNISO 9001: 2008 Certification
26th Feb 200911:09 amPRNCorrection : Holding(s) in Company
26th Feb 20099:00 amPRNHolding(s) in Company
15th Jan 20094:41 pmRNSSecond Price Monitoring Extn
15th Jan 20094:35 pmRNSPrice Monitoring Extension
6th Jan 20099:57 amPRNTrading Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.